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Abstract
Background: Early B-cell factor 1 (EBF1) is a transcription factor expressed primarily during early B cell
development. Previous studies have shown EBF1 regulates blood glucose and lipid metabolism in mice with
diabetes and central adiposity. Recently, a genetic variation (rs36071027) located in an EBF1 gene intron was
associated with carotid artery intima-media thickness. However, whether this polymorphism is actually linked with
coronary artery disease (CAD) and its severity remains unclear.
Methods: This study includes 293 CAD cases and 262 controls without CAD. All participants were devided into two
groups based on their coronary angiography results. A polymerase chain reaction-ligase detection reaction was
used to identify genotypes at rs36071027, and CAD patients were further divided into subgroups with one-, two-,
or three-vessel stenosis reflective of CAD severity.
Results: The frequency of the rs36071027 TT genotype was significantly higher in CAD cases versus controls (4.8%
vs. 1.5%, 95% CI: 1.13-10.81 P = 0.029). Subjects with a variant genotype T allele had an increased risk of CAD
compared to C allele carriers (additive model: 95% CI: 1.13-2.23, P = 0.008). After adjustment for cardiovascular risk
factors, analysis of the additive and dominant models involving rs36071027 also revealed that T allele carriers had a
significantly higher risk for CAD than C allele carriers (additive model: OR 1.56, 95% CI 1.10–2.22, P = 0.013; dominant
model: OR 1.60, 95% CI 1.07–2.41, P = 0.023). Furthermore, both diabetes and the CT + TT rs36071027 genotype
were significantly associated with three-vessel stenosis.
Conclusion: Our results in a Chinese population suggest that the TT genotype and T alleles in rs36071027 in the
EBF1 gene are associated with an increased risk of CAD and its severity.
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Background
Coronary artery disease (CAD) is one of the most common
cardiovascular diseases, and myocardial infarction (MI), as
its main complication, is the major cause of morbidity and
mortality in China [1]. Risk factors for atherosclerotic
disease include chronic inflammation, immunology, and
genetic and environmental factors, all of which interact
with each other to promote the formation of atherosclerosis
and atherosclerotic cardiovascular diseases [2]. Over
the past decade, accumulating evidence from genome-
wide association studies (GWAS) has identified a
series of genetic susceptibility loci associated with the
risk of CAD and MI [3–6].
Early B-cell factor 1 (EBF1) located on human
chromosome 5q34 is primarily expressed in early B cells,
adipocytes, and olfactory neurons [7]. As a transcription
factor, EBF1 was initially confirmed as a necessary factor
for the maturation of B lymphocytes [8] that can activate
and repress gene expression [9]. More recently, inflam-
mation and insulin signaling were shown to be regulated
by EBF1 in adipocytes, and EBF1 acts as a key integrator
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of signal transduction, chronic inflammation and metabol-
ism [10]. Moreover, inconspicuous lipodystrophy, hypotri-
glyceridemia, and hypoglycemia have also been identified
in EBF1 knockout mice [11]. Meanwhile, many EBF1 tar-
get genes have been associated with intima-media thick-
ness (IMT) of carotid artery, a marker of subclinical
atherosclerosis with high heritability [12]. Although im-
perfect, there are data supporting the hypothesis that
EBF1 plays a critical regulatory role in metabolism and is
an independent risk factor for CAD [13–16].
To our knowledge, no study has reported an associ-
ation between the single nucleotide polymorphism
(SNP) rs36071027 in the EBF1 gene with the risk of
CAD and its severity. To increase our understanding of
the functions of EBF1 in CAD and to improve our ability
to predict CAD risk earlier than that provided by current
clinical variables, we investigated the potential association
between the rs36071027 polymorphism, which is strongly
associated with carotid IMT, and the risk of CAD and its
severity in a Chinese population.
Methods
Study subjects
The study was performed on a total of 555 unrelated
individuals, which was composed of 293 CAD patients
and 262 non-CAD subjects. All participants were en-
rolled from the First Affiliated Hospital of Nanjing
Medical University between January 2013 and December
2015, and all underwent cardiac catheterization for
clinical diagnosis of CAD, including angina pectoris and
prior or acute MI. CAD was defined as a luminal
narrowing > 50% in at least one main coronary artery.
Patients with CAD were further divided into one-, two-,
and three-vessel stenosis subgroups to reflect the sever-
ity of CAD, and the control subjects were identified as
those with <20% luminal narrowing in any main coron-
ary artery [17, 18]. Exclusion criteria included those with
concomitant diseases, such as congenital heart disease,
renal failure, and malignancies. Subjects younger than
18 years were also excluded from the study. The present
study was approved by the ethics committee of the First
Affiliated Hospital of Nanjing Medical University, and
the consent form was signed by each participant.
Definition of cardiovascular risk factors
Hypertension, diabetes, smoking, and dyslipidemia are
well established independent risk factors for CAD. Patients
with a systolic blood pressure ≥ 140 mmHg and/or a dia-
stolic blood pressure ≥ 90 mmHg or taking hypertension-
lowering medicine were diagnosed with hypertension.
Diabetes was defined as having two measurements of
fasting blood glucose > 7.0 mmol/L or a random glu-
cose >11.1 mmol/L. Dyslipidemia was defined as
having a total cholesterol level > 5.72 mmol/L and/or
triglycerides > 1.70 mmol/L or the patient was under
treatment with lipid-lowering drugs. Smoking was de-
fined as smoking continuously or over consecutive
periods at least six months.
SNP genotyping
Blood samples were collected from each subject after over-
night fasting for lipids and glucose detection, and DNA was
extracted from cells using the AxyPrep DNA Blood kit
(Axygen Scientific Inc, Union City, CA, USA) and stored at
−80 °C until use. Genotyping for the SNP rs36071027 was
conducted using the polymerase chain reaction-ligase de-
tection method described previously [19, 20].
Statistical analysis
Statistical analysis was conducted with the SPSS software
version 17.0 (SPSS Inc., Chicago, IL, USA). Continuous
variables were expressed as the mean ± standard devi-
ation (SD) and the difference between continuous vari-
ables was calculated by the Student’s t test. The allele
distribution and qualitative variables expressed as fre-
quencies were compared using the chi-square (χ2) test.
For both CAD and control groups, a χ2 goodness-of-fit
test was performed with the Hardy–Weinberg equilib-
rium. An odds ratio (OR) and a 95% confidence interval
(CI) were used to determine the correlation between the
C/T polymorphism and the risk of CAD. A multiple
logistic regression analysis, adjusted for factors, includ-
ing age, gender, BMI, smoking, hypertension, diabetes,
and dyslipidemia, was used to evaluate whether the
EBF1 genetic variants and other related risk factors were
independent factors for the severity of CAD. Additionally,
we also used additive and dominant models to assess the
association of the C/T polymorphism between the CAD




The baseline data of the CAD patients and controls are
listed in Table 1. Compared with the controls, a signifi-
cantly higher proportion of patients with CAD were
affected by diabetes and smoking (all P < 0.01). However,
no significant differences were observed regarding gen-
der composition, mean age, body mass index (BMI), or
the proportion of patients affected by hypertension or
hyperlipidemia between the CAD cases and controls (all
P > 0.05). In regards to the coronary angiographic find-
ings, 93 (31.7%), 99 (33.8%), and 101 (34.5%) CAD cases
had one-, two-, and three-vessel disease, respectively.
Genotype frequencies and their associations with CAD
The genotype distribution of rs36071027 in the CAD
cases and control subjects is provided in Table 2. The
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genotype distribution of rs36071027 in the cases and
controls in this study showed no deviation from the
Hardy–Weinberg equilibrium (P > 0.05). The fre-
quency of the TT genotype of rs36071027 was sig-
nificantly higher in CAD patients than that in
controls (4.8% vs. 1.5%, P = 0.029). Compared with C
genotype allele carriers of rs36071027, the T geno-
type allele carriers had an increased risk of CAD
under the additive model (OR 1.59, 95% CI 1.13–
2.23, P = 0.008). After adjustment for cardiovascular
risk factors, analysis of the additive and dominant
models involving rs36071027 also revealed that T al-
lele carriers had a significantly higher risk for CAD
than C allele carriers (additive model: OR 1.56, 95%
CI 1.10–2.22, P = 0.013; dominant model: OR 1.60,
95% CI 1.07–2.41, P = 0.023). The multiple logistic
regression analysis showed that individuals with a
TT genotype had 2.98-fold higher risk of CAD than
CC carriers (95%CI 0.94-9.46, P = 0.064).
Gene-smoking and gene-diabetes interactions on the risk
of CAD
Further subgroup analyses were performed to determine
the effect of a gene-smoking and gene-diabetes interac-
tions. As shown in Table 3, subjects with CT + TT geno-
types or CC + smoking both had an increased risk of
CAD (OR1.72, 95% CI 1.07-2.77, P = 0.025; OR1.88, 95%
CI 1.23-2.86, P = 0.017; respectively). The smokers with
the CT + TT genotype had a 1.61-fold higher risk of
CAD than non-smoking subjects with the CC genotype
(95%CI 1.30-5.24, P = 0.009). Furthermore, subjects with
CT + TT genotypes + diabetes had higher risk of CAD
(OR3.93, 95% CI 1.74-8.89, P = 0.001) than non-diabetes
subjects with the CC genotype; however, the risk of CAD
did not increase among non-diabetes subjects carrying
CT + TT genotype (OR1.41, 95% CI 0.89-2.23, P = 0.142).
The relationship of clinical characteristics and risk factors
to the severity of CAD
The basic clinical characteristics and genotype frequency
of rs36071027 among all subjects are presented in
Table 4. Except for the distribution of sex, diabetes, and
smoking, no significant differences exist with regards to
age, BMI, hypertension, or hyperlipidemia among the
four groups, including controls and CAD patients with
one-, two-, and three-vessel stenosis. In Table 5, by using
multiple logistic regression models, we analyzed the risk
factors of coronary lesion severity between the control
subjects and the three groups of patients with CAD. The
current study revealed that only smoking, diabetes, and
a CT/TT rs36071027 genotype were significant risk
factors for three-vessel CAD (OR 2.04, 95% CI 1.08-3.87,
P = 0.028; OR 2.95, 95% CI 1.76-4.95, P < 0.001; OR 1.96,
95% CI 1.14-3.37, P = 0.015).
Discussion
In this study, we performed a hospital-based case–control
study to investigate the potential association between the
rs36071027 polymorphism and the risk of CAD and its
Table 1 Baseline characteristics of CAD cases and controls
Variables CAD cases (n = 293) Controls (n = 262) P
N (%) N (%)
Age (years) 66.72 ± 11.10 65.14 ± 12.16 0.110
Sex (male) 163 (55.6) 125 (47.7) 0.062
BMI (kg/m2) 24.93 ± 3.08 25.19 ± 3.47 0.363
Smoking, n (%) 107 (36.5) 64 (24.4) 0.002
Hypertension, n (%) 100 (34.1) 79 (30.2) 0.317
Hyperlipidemia,n (%) 106 (36.2) 85 (32.4) 0.355
Diabetes, n (%) 92 (31.4) 54 (20.6) 0.004




Age and BMI are expressed as the mean ± SD and were compared using the
Student’s t-test. Other data are expressed as frequencies and percentagesand
were compared using the χ2-test
Abbreviations: CAD, coronary artery disease; BMI, body mass index
Table 2 Association analyses of rs36071027 genotypes in the EBF1 gene between CAD patients and controls
Genotypes CAD cases (n = 293) Controls (n = 262) OR (95% CI) P Multiple adjusted
ORa (95% CI)
P
n (%) n (%)
rs36071027
CC 211 (72.0) 211 (80.5) 1 1
CT 68 (23.2) 47 (17.9) 1.45 (0.953–2.20) 0.083 1.48 (0.96–2.27) 0.074
TT 14 (4.8) 4 (1.5) 3.50 (1.13–10.81) 0.029 2.98 (0.94–9.46) 0.064
Additive model 1.59 (1.13–2.23) 0.008 1.56 (1.10–2.22) 0.013
Dominant model 1.61 (1.08–2.39) 0.019 1.60 (1.07–2.41) 0.023
Abbreviations: OR, odds ratio; CI, confidence interval
aLogistic regression model, adjusted by age, sex, hypertension, diabetes, smoking, body mass index and hyperlipidemia
Additive model: TT vs. CC. Dominant model: (TT + CT) vs. CC
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severity. Our study demonstrated that the rs36071027
variants in the EBF1 gene in a Chinese population were
significantly associated with an increased risk of CAD and
its severity, which provides novel data to this field in the
current era of “precision medicine” and helps improve our
capacity for early CAD risk prediction.
Besides being a vital gene for the development and
differentiation of B lymphocytes, EBF1 is also involved
in the differentiation of adipose lineage cells [21, 22].
Studies in knockout mice have revealed a function for
EBF1 in metabolism due to mouse phenotypes including
lipodystrophy, hypotriglyceridemia, and hypoglycemia
[11]. Compared with the wild type controls, the symp-
tom of lipodystrophy in the EBF1 knockout mice is char-
acterized by additional brown adipose tissue and a
striking reduction in white adipose tissue in the bone
marrow [11, 23]. Recently, scholars have determined that
EBF1’s function in early B-cell development could be
inhibited by active NOTCH signaling [24]. Moreover,
the NOTCH1 signal pathway plays a critical regulatory
role in the formation of unstable atherosclerotic plaques
[25] and is activated in a rat model of post-acute MI
[26]. These data support the role of EBF1 gene variants
and the NOTCH signaling pathway in regulating metab-
olism of fatty acids and lipids and the formation of
vulnerable atherosclerotic plaques.
In terms of previous GWAS results identifying gene
variants significantly associated with cardiovascular dis-
eases in a European population [27, 28]. The EBF1 gene
has also been identified as potential critical regulatory
Table 3 Gene-smoking and gene-diabetes interaction in patients with CAD cases and controls
Variables CAD cases Controls OR (95% CI) P adjusted OR a (95% CI) P
rs36071027 Smoking
CC No 132 (45.1) 160 (61.1) 1 1
CC Yes 79 (27.0) 51 (19.5) 1.88 (1.23–2.86) 0.003 1.89 (1.15–3.12) 0.012
CT + TT No 54 (18.4) 38 (14.5) 1.72 (1.07–2.77) 0.025 1.80 (1.11–2.93) 0.017
CT + TT Yes 28 (9.6) 13 (5.0) 2.61 (1.30–5.24) 0.007 2.55 (1.22–5.30) 0.013
Pinteration 0.882 0.747
rs36071027 Diabetes
CC No 147 (50.2) 165 (63.0) 1 1
CC Yes 64 (21.8) 46 (17.6) 1.56 (1.01–2.42) 0.047 1.58 (1.00–2.49) 0.050
CT + TT No 54 (18.4) 43 (16.4) 1.41 (0.89–2.23) 0.142 1.40 (0.88–2.23) 0.160
CT + TT Yes 28 (9.6) 8 (3.1) 3.93 (1.74–8.89) 0.001 3.84 (1.68–8.78) 0.001
Pinteration 0.249 0.280
Abbreviations: OR, odds ratio; CI, confidence interval
aLogistic regression model, adjusted by age, sex, hypertension, diabetes, smoking, body mass index and hyperlipidemia
Table 4 Clinical characteristics in controls and CAD patients with different vessel lesions
Variables Number of involved vessels P
0 (n = 262) 1 (n = 93) 2 (n = 99) 3 (n = 101)
Age (years) 66.14 ± 12.16 66.84 ± 11.93 66.36 ± 10.83 69.97 ± 10.66 0.439
Sex (male) 125 (47.7) 46 (49.5) 64 (64.6) 53 (52.5) 0.036
BMI (kg/m2) 25.19 ± 3.47 24.58 ± 3.04 25.37 ± 3.07 24.83 ± 3.10 0.294
Smoking,n (%) 64 (24.4) 26 (28.0) 43 (43.4) 38 (37.6) 0.002
Hypertension, n (%) 183 (69.8) 57 (61.3) 67 (67.7) 69 (68.3) 0.509
Hyperlipidemia, n (%) 85 (32.4) 32 (34.4) 33 (33.3) 41 (40.6) 0.530
Diabetes,n (%) 54 (20.6) 19 (20.4) 29 (29.3) 44 (43.6) <0.001
rs36071027
CC 211 (80.5) 67 (72.0) 76 (76.8) 68 (67.3) 0.068
CT 47 (17.9) 23 (24.7) 19 (19.2) 26 (25.7)
TT 4 (1.5) 3 (3.2) 4 (4.0) 7 (6.9)
Abbreviations: OR, odds ratio; CI, confidence interval
Age and BMI are expressed as the mean ± SD and were compared using the Student’s t-test. Other data are expressed as frequencies and percentages and were
compared using the χ2-test
Li et al. BMC Cardiovascular Disorders  (2017) 17:57 Page 4 of 7
gene for the formation of atherosclerosis and CAD
[13–16]. Scholars [12] revealed that the rs36071027
variant in the EBF1 gene increases the risk of IMT,
which is not only significantly associated with the
severity of CAD, but is also a screening index of CAD. In
the present study, the rs36071027 TT genotype frequency
in CAD patients was significantly higher than in controls.
Participants with the rs36071027 TT genotype or a T allele
were more susceptible to CAD than those with the CC
genotype or a C allele. These findings are consistent with
the role of EBF1 gene variants found in previous studies.
In the present study, there is higher proportion of
smoking and diabetes in the CAD group than in the
control group. Smoking is well-known to be one of the
main risk factors for CAD. Smoking contributes to the
inflammatory process through promoting the release of
inflammatory cytokines, such as C-reactive protein,
interleukin-1 and tumor necrosis factor-α. Furthermore,
inflammation can interact with lipoprotein metabolism
and influence endothelial function [29]. In the current
study, using an interaction model theory, the interaction
between smoking and the genotype was used to explore
gene loci and the interaction of smoking and their rela-
tionship with the risk of CAD. Interestingly, our results
showed that being a carrier of the rs36071027 CT/TT
genotypes or smoking both could increase the risk for
CAD, although the interaction effect between the CT/
TT rs36071207 genotypes and smoking on the risk of
CAD was similar to either factor alone. Furthermore,
only subjects with CT + TT genotypes and diabetes had
increased risk of CAD compared to non-diabetes sub-
jects with the CC genotype.
As another important risk factor for CAD, diabetes
has a common environmental and genetic basis with
CAD, which is the key concept of the theory of “com-
mon ground’ of CAD and diabetes [30]. Furthermore,
Cutlip DE et al. found that comorbid diabetes is the
strongest predictor of clinical vascular restenosis after a
coronary intervention [31]. In the present study, a multi-
variate logistic regression model showed that diabetes
and the rs36071027 CC + TT genotype have a significant
association with the severity of CAD.
Limitations
This study has several limitations. First, this was an
observational study, and the sample size was relatively
small, which might under-power the results of our study.
Second, because of the case–control design, selection
bias might affect our findings. Furthermore, since all
control subjects have suspicion of having significant
CAD although severe coronary stenosis was ruled out by
coronary angiography, the control group does not repre-
sent a general healthy population, and more concomi-
tant risk factors could be assumed in the control group
compared to the general population. Furthermore, the
present study lacks direct cause-and-effect evidence
indicating whether the variations of rs36071027 in the
EBF1 gene are functional or not, and the pathogenic
mechanism for these variants to induce CAD has not
been determined. Finally, our study sample came from a
Chinese population, and applying these results to other
ethnic groups should be done with caution. However,
our study obviously provides valuable information to
future studies connecting the EBF1 gene and CAD.
Conclusion
This study observes for the first time that the TT
genotype at rs36071027 increases the risk of CAD,
and the rs36071027 CT + TT genotype can potentially
be used as a gene marker to predict the severity of
CAD. Our study results provide new biological in-
sights into EBF1 variants and CAD risk and may
identify novel targets for the prevention of cardiovas-
cular disease. Nevertheless, further studies are neces-
sary in order to fully elucidate the role of EBF1 in
the pathogenesis of CAD.
Table 5 The rs36071027 polymorphism and other risk factors in 1-,2-, and 3-vessel disease patients compared with non-CAD
subjects by a logistic regression
Variables One-vessel disease Two-vessel disease Three- vessel disease
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Age 1.02 (1.00–1.04) 0.117 1.01 (0.99–1.03) 0.254 1.01 (0.99–1.03) 0.347
Sex 1.00 (0.55–1.81) 0.996 0.72 (0.39–1.31) 0.280 1.10 (0.60–2.02) 0.757
BMI 0.95 (0.88–1.02) 0.170 1.02 (0.95–1.09) 0.643 0.97 (0.90–1.05) 0.469
Smoking 1.23 (0.63–2.38) 0.548 2.04 (1.11–3.76) 0.023 2.04 (1.08–3.87) 0.028
Hypertension 0.61 (0.36–1.04) 0.067 0.89 (0.52–1.50) 0.658 0.82 (0.48–1.41) 0.478
Hyperlipidemia 1.16 (0.69–1.94) 0.580 1.12 (0.67–1.86) 0.675 1.48 (0.90–2.46) 0.124
Diabetes 1.02 (0.56–1.88) 0.940 1.60 (0.92–2.78) 0.097 2.95 (1.76–4.95) <0.001
rs36071027 (CT + TT vs. CC) 1.67 (0.96–2.91) 0.071 1.27 (0.71–2.26) 0.420 1.96 (1.14–3.37) 0.015
Abbreviations: OR, odds ratio; CI, confidence interval
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Additional file
Additional file 1: Clinical data of CAD cases and controls from 2013 to
2015. For the convenience of data analysis, Arabic numbers were used to
describe the patient’s specific characteristics and the details were placed
in the first line of the Additional file 1. (XLSX 40 kb)
Abbreviations
EBF1: Early B-cell factor 1; CAD: Coronary artery disease; MI: Myocardial
infarction; GWAS: Genome-wide association studies; IMT: Intima-media
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